Argus Research Upgrades CVS Caremark to "Buy" (CVS)

Argus Research Upgrades CVS Caremark to “Buy” (CVS)


Drug store chain CVS Caremark Corporation (CVS) was upgraded by analysts at Argus Research on Wednesday.

The analysts upgraded CVS to “Buy” and see shares reaching $64, up from the previous target of $58. This new target suggests an 11% upside to Tuesday’s closing price of $57.63.

CVS shares were down 27 cents, or -0.47%, during morning trading on Wednesday. The stock is up +18.8% year-to-date.

The Bottom Line
Shares of CVS Caremark Corporation (CVS) have a dividend yield of 1.57% based on Wednesday’s intraday trading price of $57.41 and the company’s annualized dividend payout of 90 cents per share.

CVS Caremark Corporation (CVS) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today